Bli medlem
Bli medlem

Du är här


Myriad Genetics, Inc.: Crescendo Bioscience's Vectra(R) DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis

New Study Data Published in Annals of Rheumatic Diseases Add to Clinical EvidenceSALT LAKE CITY, May 14, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a
wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today
announced the online publication of a new study in the journalAnnals of the
Rheumatic Diseases
for Crescendo's Vectra DA blood test. The study is a retrospective analysis of
data from the Swedish Farmacotherapy (SWEFOT) clinical trial and shows that
Vectra DA is a strong predictor of radiographically visible damage to joints,
known as disease progression, in patients newly diagnosed with rheumatoid
arthritis (RA). Vectra DA is the only multi-biomarker blood test validated to
assess disease activity in patients with rheumatoid arthritis.

This study evaluated the Vectra DA test score as a predictor of one-year
radiographic progression in 235 patients in SWEFOT. All patients had early
rheumatoid arthritis and had not been previously treated with a
disease-modifying anti-rheumatic drug (DMARD). The results showed that the
Vectra DA score at baseline was an independent predictor of radiographic
progression over one year of DMARD treatment. Among the 201 patients with a
high Vectra DA score at baseline, 21 percent had radiographic progression at
one year. By contrast, of the 34 patients with a low/moderate Vectra DA
score, only 3.4 percent had radiographic progression at one year, confirming
that patients who do not have a high score are at low risk of progression.
Vectra DA also effectively differentiated patients with and without disease
progression better than the C-reactive protein (CRP) test, and other
traditional measures of disease activity, including DAS28-CRP. These findings
underscore the clinical value of Vectra DA for predicting disease progression
in newly diagnosed patients with RA and its potential to help doctors manage
patients based on their risk of disease progression. Importantly, these
findings build on earlier results from the Leiden Early Arthritis Cohort
study published inRheumatology (Oxford)
, which showed that patients with a high Vectra DA score were at a six-fold
higher risk of disease progression than those with a low Vectra DA score.

"Our study demonstrates that Vectra DA provides highly relevant clinical
information in patients with newly diagnosed rheumatoid arthritis," said
Ronald F. van Vollenhoven, M.D., Ph.D, Department of Medicine, Karolinska
University Hospital in Stockholm, Sweden. "With this test taken before
anti-rheumatic therapies are started, the clinician will have more knowledge
about the patient's prognosis to help inform decisions regarding treatment,
an important step toward personalized medicine in the treatment of this
important musculoskeletal disease."

About Vectra DA

Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA)
disease activity that integrates the concentrations of 12 serum proteins
associated with RA disease activity into a single objective score, on a scale
of 1 to 100, to help physicians make more informed treatment decisions.
Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art
CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are
reported to the physician 5 to 7 days from shipping of the specimen to
Crescendo Bioscience. Physicians can receive test results via standard mail,
by fax or via the private web portal, VectraView. For more information on
Vectra DA, please visit,

About Crescendo Bioscience

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a
molecular diagnostics company dedicated to developing and commercializing
quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune
diseases, located in South San Francisco, California. Crescendo Bioscience
develops quantitative, objective, blood tests to provide rheumatologists with
deeper clinical insight to help enable more effective management of patients
with autoimmune and inflammatory diseases. For more information, please visit
the company's website

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making
a difference in patients' lives through the discovery and commercialization
of transformative tests to assess a person's risk of developing disease,
guide treatment decisions and assess risk of disease progression and
recurrence. Myriad's molecular diagnostic tests are based on an understanding
of the role genes play in human disease and were developed with a commitment
to improving an individual's decision making process for monitoring and
treating disease. Myriad is focused on strategic directives to introduce new
products, including companion diagnostics, as well as expanding
internationally. For more information on how Myriad is making a difference,
please visit the Company's

Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan, Myriad
myRisk, and Vectra are trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the Vectra DA clinical study data;
the significant clinical value of Vectra DA which may help doctors manage
patients based on their risk of disease progression; the effectiveness of
Vectra DA testing to accurately predict disease progression in patients newly
diagnosed with rheumatoid arthritis (RA); and the Company's strategic
directives under the captions "About Vectra DA," "About Crescendo Bioscience"
and "About Myriad Genetics." These "forward-looking statements" are
management's present expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to differ
materially and adversely from those described in the forward-looking
statements. These risks include, but are not limited to: the risk that sales
and profit margins of our existing molecular diagnostic tests and companion
diagnostic services may decline or will not continue to increase at
historical rates; risks related to changes in the governmental or private
insurers reimbursement levels for our tests; the risk that we may be unable
to develop or achieve commercial success for additional molecular diagnostic
tests and companion diagnostic services in a timely manner, or at all; the
risk that we may not successfully develop new markets for our molecular
diagnostic tests and companion diagnostic services, including our ability to
successfully generate revenue outside the United States; the risk that
licenses to the technology underlying our molecular diagnostic tests and
companion diagnostic services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays or other
problems with operating our laboratory testing facilities; risks related to
public concern over our genetic testing in general or our tests in
particular; risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of the
healthcare system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks related to
our ability to successfully integrate and derive benefits from any
technologies or businesses that we license or acquire; risks related to
increased competition and the development of new competing tests and
services; the risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying our
tests; the risk of patent-infringement claims or challenges to the validity
of our patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and companion diagnostic services and
patents or enforcement in the United States and foreign countries, such as
the Supreme Court decision in the lawsuit brought against us by the
Association for Molecular Pathology et al; risks of new, changing and
competitive technologies and regulations in the United States and
internationally; and other factors discussed under the heading "Risk Factors"
contained in Item 1A of our most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission, as well as any updates to those risk
factors filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K. All information in this press release is as of
the date of the release, and Myriad undertakes no duty to update this
information unless required by law.

CONTACT: Media Contact:
Ron Rogers
(801) 584-3065

Investor Contact:
Scott Gleason
(801) 584-1143


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Myriad Genetics, Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.